<?xml version='1.0' encoding='utf-8'?>
<document id="31445021"><sentence text="Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202."><entity charOffset="95-105" id="DDI-PubMed.31445021.s1.e0" text="dabrafenib" /><entity charOffset="107-116" id="DDI-PubMed.31445021.s1.e1" text="ibrutinib" /><entity charOffset="118-128" id="DDI-PubMed.31445021.s1.e2" text="nintedanib" /><entity charOffset="130-140" id="DDI-PubMed.31445021.s1.e3" text="trametinib" /><pair ddi="false" e1="DDI-PubMed.31445021.s1.e0" e2="DDI-PubMed.31445021.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31445021.s1.e0" e2="DDI-PubMed.31445021.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s1.e0" e2="DDI-PubMed.31445021.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s1.e0" e2="DDI-PubMed.31445021.s1.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s1.e1" e2="DDI-PubMed.31445021.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s1.e1" e2="DDI-PubMed.31445021.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s1.e1" e2="DDI-PubMed.31445021.s1.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s1.e2" e2="DDI-PubMed.31445021.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s1.e2" e2="DDI-PubMed.31445021.s1.e3" /></sentence><sentence text="We have demonstrated previously that the kinase inhibitors (KIs) lapatinib, pazopanib, regorafenib and sorafenib are potent inhibitors of UGT1A1 and UGTs 1A7-1A10"><entity charOffset="65-74" id="DDI-PubMed.31445021.s2.e0" text="lapatinib" /><entity charOffset="76-85" id="DDI-PubMed.31445021.s2.e1" text="pazopanib" /><entity charOffset="87-98" id="DDI-PubMed.31445021.s2.e2" text="regorafenib" /><entity charOffset="103-112" id="DDI-PubMed.31445021.s2.e3" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.31445021.s2.e0" e2="DDI-PubMed.31445021.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31445021.s2.e0" e2="DDI-PubMed.31445021.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s2.e0" e2="DDI-PubMed.31445021.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s2.e0" e2="DDI-PubMed.31445021.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s2.e1" e2="DDI-PubMed.31445021.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s2.e1" e2="DDI-PubMed.31445021.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s2.e1" e2="DDI-PubMed.31445021.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s2.e2" e2="DDI-PubMed.31445021.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s2.e2" e2="DDI-PubMed.31445021.s2.e3" /></sentence><sentence text=" The present study characterised the effects of four additional drugs in this class, dabrafenib, ibrutinib, nintedanib and trametinib, on human UGT enzyme activities in vitro"><entity charOffset="85-95" id="DDI-PubMed.31445021.s3.e0" text="dabrafenib" /><entity charOffset="97-106" id="DDI-PubMed.31445021.s3.e1" text="ibrutinib" /><entity charOffset="108-118" id="DDI-PubMed.31445021.s3.e2" text="nintedanib" /><entity charOffset="123-133" id="DDI-PubMed.31445021.s3.e3" text="trametinib" /><pair ddi="false" e1="DDI-PubMed.31445021.s3.e0" e2="DDI-PubMed.31445021.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31445021.s3.e0" e2="DDI-PubMed.31445021.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s3.e0" e2="DDI-PubMed.31445021.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s3.e0" e2="DDI-PubMed.31445021.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s3.e1" e2="DDI-PubMed.31445021.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s3.e1" e2="DDI-PubMed.31445021.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s3.e1" e2="DDI-PubMed.31445021.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s3.e2" e2="DDI-PubMed.31445021.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s3.e2" e2="DDI-PubMed.31445021.s3.e3" /></sentence><sentence text=" Dabrafenib, ibrutinib, nintedanib and trametinib were potent inhibitors of human liver microsomal UGT1A1; Ki,u values ranged from 1"><entity charOffset="1-11" id="DDI-PubMed.31445021.s4.e0" text="Dabrafenib" /><entity charOffset="13-22" id="DDI-PubMed.31445021.s4.e1" text="ibrutinib" /><entity charOffset="24-34" id="DDI-PubMed.31445021.s4.e2" text="nintedanib" /><entity charOffset="39-49" id="DDI-PubMed.31445021.s4.e3" text="trametinib" /><pair ddi="false" e1="DDI-PubMed.31445021.s4.e0" e2="DDI-PubMed.31445021.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31445021.s4.e0" e2="DDI-PubMed.31445021.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s4.e0" e2="DDI-PubMed.31445021.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s4.e0" e2="DDI-PubMed.31445021.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s4.e1" e2="DDI-PubMed.31445021.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s4.e1" e2="DDI-PubMed.31445021.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s4.e1" e2="DDI-PubMed.31445021.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s4.e2" e2="DDI-PubMed.31445021.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s4.e2" e2="DDI-PubMed.31445021.s4.e3" /></sentence><sentence text="1 to 7" /><sentence text="5 µM" /><sentence text=" Similarly, these KIs inhibited UGT 1A7, 1A8, 1A9 and 1A10, albeit less potently than UGT1A1" /><sentence text=" Despite the potent inhibition of UGT1A1, in vitro - in vivo extrapolation excluded the likelihood that dabrafenib, ibrutinib, nintedanib and trametinib would precipitate drug-drug interactions (DDIs) due to the low unbound plasma concentrations of these drugs observed in patients"><entity charOffset="104-114" id="DDI-PubMed.31445021.s8.e0" text="dabrafenib" /><entity charOffset="116-125" id="DDI-PubMed.31445021.s8.e1" text="ibrutinib" /><entity charOffset="127-137" id="DDI-PubMed.31445021.s8.e2" text="nintedanib" /><entity charOffset="142-152" id="DDI-PubMed.31445021.s8.e3" text="trametinib" /><pair ddi="false" e1="DDI-PubMed.31445021.s8.e0" e2="DDI-PubMed.31445021.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31445021.s8.e0" e2="DDI-PubMed.31445021.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s8.e0" e2="DDI-PubMed.31445021.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s8.e0" e2="DDI-PubMed.31445021.s8.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s8.e1" e2="DDI-PubMed.31445021.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s8.e1" e2="DDI-PubMed.31445021.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s8.e1" e2="DDI-PubMed.31445021.s8.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s8.e2" e2="DDI-PubMed.31445021.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s8.e2" e2="DDI-PubMed.31445021.s8.e3" /></sentence><sentence text=" The structures of dabrafenib, ibrutinib, lapatinib, nintedanib, pazopanib, regorafenib, trametinib and 22 other KIs overlaid well on that of sorafenib, a potent inhibitor of UGT1A1 and UGTs 1A7-1A10"><entity charOffset="19-29" id="DDI-PubMed.31445021.s9.e0" text="dabrafenib" /><entity charOffset="31-40" id="DDI-PubMed.31445021.s9.e1" text="ibrutinib" /><entity charOffset="42-51" id="DDI-PubMed.31445021.s9.e2" text="lapatinib" /><entity charOffset="53-63" id="DDI-PubMed.31445021.s9.e3" text="nintedanib" /><entity charOffset="65-74" id="DDI-PubMed.31445021.s9.e4" text="pazopanib" /><entity charOffset="76-87" id="DDI-PubMed.31445021.s9.e5" text="regorafenib" /><entity charOffset="89-99" id="DDI-PubMed.31445021.s9.e6" text="trametinib" /><entity charOffset="142-151" id="DDI-PubMed.31445021.s9.e7" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e0" e2="DDI-PubMed.31445021.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e0" e2="DDI-PubMed.31445021.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e0" e2="DDI-PubMed.31445021.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e0" e2="DDI-PubMed.31445021.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e0" e2="DDI-PubMed.31445021.s9.e4" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e0" e2="DDI-PubMed.31445021.s9.e5" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e0" e2="DDI-PubMed.31445021.s9.e6" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e0" e2="DDI-PubMed.31445021.s9.e7" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e1" e2="DDI-PubMed.31445021.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e1" e2="DDI-PubMed.31445021.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e1" e2="DDI-PubMed.31445021.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e1" e2="DDI-PubMed.31445021.s9.e4" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e1" e2="DDI-PubMed.31445021.s9.e5" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e1" e2="DDI-PubMed.31445021.s9.e6" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e1" e2="DDI-PubMed.31445021.s9.e7" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e2" e2="DDI-PubMed.31445021.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e2" e2="DDI-PubMed.31445021.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e2" e2="DDI-PubMed.31445021.s9.e4" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e2" e2="DDI-PubMed.31445021.s9.e5" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e2" e2="DDI-PubMed.31445021.s9.e6" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e2" e2="DDI-PubMed.31445021.s9.e7" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e3" e2="DDI-PubMed.31445021.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e3" e2="DDI-PubMed.31445021.s9.e4" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e3" e2="DDI-PubMed.31445021.s9.e5" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e3" e2="DDI-PubMed.31445021.s9.e6" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e3" e2="DDI-PubMed.31445021.s9.e7" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e4" e2="DDI-PubMed.31445021.s9.e4" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e4" e2="DDI-PubMed.31445021.s9.e5" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e4" e2="DDI-PubMed.31445021.s9.e6" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e4" e2="DDI-PubMed.31445021.s9.e7" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e5" e2="DDI-PubMed.31445021.s9.e5" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e5" e2="DDI-PubMed.31445021.s9.e6" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e5" e2="DDI-PubMed.31445021.s9.e7" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e6" e2="DDI-PubMed.31445021.s9.e6" /><pair ddi="false" e1="DDI-PubMed.31445021.s9.e6" e2="DDI-PubMed.31445021.s9.e7" /></sentence><sentence text=" Taken together, kinetic and computational modelling data suggest that all currently marketed KIs are likely to be potent inhibitors of UGT1A1, and are also likely to inhibit UGTs 1A7-1A10 to some extent due to the structural and chemical features shared in common by these drugs" /><sentence text=" By contrast, BIBF 1202, the major metabolite of nintedanib, did not appreciably inhibit human UGTs, due to the presence of a terminal electronegative group which appears to disfavor enzyme inhibition"><entity charOffset="49-59" id="DDI-PubMed.31445021.s11.e0" text="nintedanib" /></sentence><sentence text=" Given the potent inhibition of several UGT enzymes, especially UGT1A1, by KIs, characterisation of the DDI potential of newly developed agents in this class is warranted" /><sentence text="" /></document>